Loading...
Aytu BioPharma, Inc.
AYTU•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$2.63
$-0.02(-0.94%)
Aytu BioPharma, Inc. (AYTU) Financial Performance & Income Statement Overview
Review Aytu BioPharma, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-24.58%
↓ 24.58%
Operating Income Growth
69.21%
↑ 69.21%
Net Income Growth
7.07%
↑ 7.07%
Operating Cash Flow Growth
72.94%
↑ 72.94%
Operating Margin
-5.57%
↓ 5.57%
Gross Margin
68.59%
↑ 68.59%
Net Profit Margin
2.37%
↑ 2.37%
ROE
5.32%
↑ 5.32%
ROIC
-7.20%
↓ 7.20%
Aytu BioPharma, Inc. (AYTU) Income Statement & Financial Overview
Review Aytu BioPharma, Inc.'s (AYTU) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $16.22M | $16.57M | $17.98M | $17.99M |
| Cost of Revenue | $5.43M | $4.59M | $6.07M | $6.30M |
| Gross Profit | $10.79M | $11.98M | $11.91M | $11.69M |
| Gross Profit Ratio | $0.66 | $0.72 | $0.66 | $0.65 |
| R&D Expenses | $522000.00 | $426000.00 | $1.04M | $619000.00 |
| SG&A Expenses | $9.72M | $10.78M | $11.09M | $11.99M |
| Operating Expenses | $12.48M | $11.21M | $15.56M | $12.61M |
| Total Costs & Expenses | $15.68M | $17.50M | $21.63M | $18.91M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.08M | $994000.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.34M | $1.43M | $1.94M | $1.80M |
| EBITDA | $2.80M | $3.92M | -$5.98M | -$842000.00 |
| EBITDA Ratio | $0.17 | $0.24 | -$0.33 | -$0.05 |
| Operating Income | -$1.70M | -$930000.00 | -$3.65M | -$2.46M |
| Operating Income Ratio | -$0.10 | -$0.06 | -$0.20 | -$0.14 |
| Other Income/Expenses (Net) | $2.08M | $2.43M | -$272000.00 | -$178000.00 |
| Income Before Tax | $382000.00 | $1.50M | -$3.92M | -$2.64M |
| Income Before Tax Ratio | $0.02 | $0.09 | -$0.22 | -$0.15 |
| Income Tax Expense | -$283000.00 | $405000.00 | $695000.00 | -$245000.00 |
| Net Income | $788000.00 | $1.47M | -$4.62M | -$2.89M |
| Net Income Ratio | $0.05 | $0.09 | -$0.26 | -$0.16 |
| EPS | $0.13 | $0.20 | -$0.83 | -$0.52 |
| Diluted EPS | -$0.26 | $0.16 | -$0.83 | -$0.52 |
| Weighted Avg Shares Outstanding | $6.13M | $7.37M | $5.54M | $5.53M |
| Weighted Avg Shares Outstanding (Diluted) | $8.49M | $9.10M | $5.54M | $5.53M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan